Ventricular Tachycardia (VT)NCT07501819
Sympathetic Ablation for Ventricular Arrhythmias
A study testing Central sympathetic nerve ablation in people with Ventricular Tachycardia (VT), run by SymKardia.
Trial summary
Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ventricular Tachycardia (VT)
- What is being tested?
- Central sympathetic nerve ablation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 10 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Sep 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 or older at the time of informed consent
- Willing and capable of providing written informed consent
- Implanted ICD or CRT-D
- Recurrent VT leading to ICD therapy (ATP or shock)
- Indicated for catheter ablation of VT per international guidelines
- No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia
Who cannot join
- Contraindication to percutaneous femoral arterial access
- Heparin-induced thrombotic thrombocytopenia
- Prior surgical sympathectomy
- ECMO therapy in the past 30 days
- Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)
- A most recently documented LVEF <20% in the past 30 days
Show all 10Show fewer
- Receiving inotropic drug therapy
- Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment
- A life expectancy of less than 12 months according to physician judgment
- Involvement in any concurrent clinical study with an investigational therapy
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias
Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.
Read the detailed description
The autonomic nervous system controls cardiac activity, and sympathetic hyperactivity is an important factor in triggering and sustaining cardiac arrhythmias such as ventricular tachycardia (VT). The objective of this study is to evaluate a new treatment for VT that targets a specific nerve that is part of the sympathetic system. In an acute procedure, an ablation catheter will be inserted into the femoral artery and guided to locations near the heart. Radiofrequency energy will be delivered to ablate the neural targets, and the catheter will be removed. Patients will be subsequently followed to determine safety and post-ablation reduction in VT frequency.
- Conditions
- Ventricular Tachycardia (VT)
- Being tested
- Central sympathetic nerve ablation
- Medical subject headings
- Tachycardia, Ventricular
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Central sympathetic nerve ablationDevice
Catheter-based ablation of an extra-cardiac nerve target
| Study group | Role | What they receive |
|---|---|---|
| Therapy | Experimental | Central sympathetic nerve ablation therapy Receives: Device: Central sympathetic nerve ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Freedom from device and procedure-related serious adverse events (SAEs)
Measured: 3 months
VT burden (episodes per month)
VT burden post-ablation will be compared to VT burden pre-ablation
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study startApr 2026 (estimated)
- Primary completionDec 2026 (estimated)
- Study completionSep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ventricular Tachycardia (VT)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 10 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SymKardia
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07501819
- Sponsor's protocol ID
- SK-001
- Status last verified
- Mar 2026
- First submitted
- 24 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias
- ClinicalTrials.gov ID
- NCT07501819
- Acronym / sponsor ID
- SK-001
- Conditions
- Ventricular Tachycardia (VT)
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 10 participants (estimated)
- Lead sponsor
- SymKardiaIndustry (pharma, biotech, devices)
- Study start
- Apr 2026 (estimated)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Sep 2027 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.
Detailed description
The autonomic nervous system controls cardiac activity, and sympathetic hyperactivity is an important factor in triggering and sustaining cardiac arrhythmias such as ventricular tachycardia (VT). The objective of this study is to evaluate a new treatment for VT that targets a specific nerve that is part of the sympathetic system. In an acute procedure, an ablation catheter will be inserted into the femoral artery and guided to locations near the heart. Radiofrequency energy will be delivered to ablate the neural targets, and the catheter will be removed. Patients will be subsequently followed to determine safety and post-ablation reduction in VT frequency.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Therapy | Experimental | Device: Central sympathetic nerve ablationCentral sympathetic nerve ablation therapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age 18 or older at the time of informed consent
- Willing and capable of providing written informed consent
- Implanted ICD or CRT-D
- Recurrent VT leading to ICD therapy (ATP or shock)
- Indicated for catheter ablation of VT per international guidelines
Key exclusion criteria (10 listed)
- Contraindication to percutaneous femoral arterial access
- Heparin-induced thrombotic thrombocytopenia
- Prior surgical sympathectomy
- ECMO therapy in the past 30 days
- Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Central sympathetic nerve ablationCatheter-based ablation of an extra-cardiac nerve target | Device | Therapy |
Primary outcome
Freedom from device and procedure-related serious adverse events (SAEs)
Time frame: 3 months
VT burden (episodes per month)
Time frame: 3 months
VT burden post-ablation will be compared to VT burden pre-ablation
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Ventricular Tachycardia (VT)
Recruiting
Safety and Effectiveness of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere VT)
Ventricular Tachycardia
Not yet recruiting
Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan
Atrial Fibrillation (AF), Atrial Flutter
Not yet recruiting
Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program VERITAS SCAR VT
Scar-related Monomorphic Sustained VT
Active, not recruitingObservational study
Evolution of Intracardiac Electrograms Recorded by Left Bundle Branch Pacing Lead in Patients With ICD or CRT-D
Ventricular Tachycardia (VT), Ventricular Fibrillation
Not yet recruiting
VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
Ventricular Tachycardia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Central sympathetic nerve ablation in people with Ventricular Tachycardia (VT), run by SymKardia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Imad Libbus, PhD (651-242-4431, imad.libbus@symkardia.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Freedom from device and procedure-related serious adverse events (SAEs) (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.